Abstract
In continuance of our search for anticonvulsant agents, we reported herein the synthesis, characterization and anticonvulsant evaluation of some newer semicarbazone analogues. A few compounds were also screened for neuroprotection assay. Some of the compounds showed significant anticonvulsant activity. Compound 4a showed 25% (1/4, 0.25 h), 75% (3/4, 0.5 & 2.0 h) and 100% (4/4, 1.0 h) protection against 6 Hz psychomotor seizure test at 100 mg/kg devoid of any neurotoxicity. Compound 4d showed neuroprotection activity with 26.3 ± 2.3 percent of total propidium iodide uptake at 100 μM and IC50 of the compound was calculated using dose response curve by probit analysis and was found to be 149 ± 1.22 μM.
Keywords: Anticonvulsant agents, 6 Hz psychomotor seizure test, Maximal electroshock seizure, Neurotoxicity, Semicarbazones.
Central Nervous System Agents in Medicinal Chemistry
Title:Psychomotor Seizure Test, Neurotoxicity and in vitro Neuroprotection Assay of some Semicarbazone Analogues
Volume: 13 Issue: 2
Author(s): Mohamed Jawed Ahsan and James P. Stables
Affiliation:
Keywords: Anticonvulsant agents, 6 Hz psychomotor seizure test, Maximal electroshock seizure, Neurotoxicity, Semicarbazones.
Abstract: In continuance of our search for anticonvulsant agents, we reported herein the synthesis, characterization and anticonvulsant evaluation of some newer semicarbazone analogues. A few compounds were also screened for neuroprotection assay. Some of the compounds showed significant anticonvulsant activity. Compound 4a showed 25% (1/4, 0.25 h), 75% (3/4, 0.5 & 2.0 h) and 100% (4/4, 1.0 h) protection against 6 Hz psychomotor seizure test at 100 mg/kg devoid of any neurotoxicity. Compound 4d showed neuroprotection activity with 26.3 ± 2.3 percent of total propidium iodide uptake at 100 μM and IC50 of the compound was calculated using dose response curve by probit analysis and was found to be 149 ± 1.22 μM.
Export Options
About this article
Cite this article as:
Ahsan Jawed Mohamed and Stables P. James, Psychomotor Seizure Test, Neurotoxicity and in vitro Neuroprotection Assay of some Semicarbazone Analogues, Central Nervous System Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/18715249113139990014
DOI https://dx.doi.org/10.2174/18715249113139990014 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and Validation of 'Level A' In Vitro - In Vivo Correlation for Extended Release Tablets of Lamotrigine
Current Bioactive Compounds NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Synthesis and Pharmacological Screening of Novel 1,3-Disubstituted 5-Pyrazolones as Anticonvulsant Agents
Current Bioactive Compounds The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Focusing on the Interactions between the GABAergic System and Neurosteroids in Neurodevelopmental Disorders
Current Pharmaceutical Design GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial
Current Medical Imaging Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery